USFDA concludes PAI at Jubilant Pharmova’s arm's facility at Roorkee

02 Aug 2025 Evaluate

United States Food and Drug Administration (USFDA) has concluded pre-approval inspection (PAI) at Jubilant Pharmova’s stepdown subsidiary -- Jubilant Generics' solid dosage formulations facility at Roorkee site, India.  The USFDA has issued 4 observations pursuant to the completion of audit. The company will submit an action plan on the observations.

The site’s revenue from the US market in the trailing twelve-month period (July 2024 to June 2025) is less than one percent of Jubilant Pharmova revenues in the same period.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.

Jubilant Pharmova Share Price

1078.00 8.80 (0.82%)
05-Dec-2025 14:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.50
Dr. Reddys Lab 1275.55
Cipla 1525.60
Zydus Lifesciences 933.80
Lupin 2101.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×